Last reviewed · How we verify
Erythropoietin carried on chitosan carrier
Erythropoietin stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells, delivered via a chitosan carrier for improved bioavailability and sustained release.
Erythropoietin stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells, delivered via a chitosan carrier for improved bioavailability and sustained release. Used for Anemia associated with chronic kidney disease, Anemia in cancer patients receiving chemotherapy.
At a glance
| Generic name | Erythropoietin carried on chitosan carrier |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Erythropoietin (EPO) is a glycoprotein hormone that activates the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and survival. The chitosan carrier is a biocompatible polysaccharide designed to enhance drug stability, enable sustained release, and potentially improve mucosal or systemic absorption of the EPO payload.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in cancer patients receiving chemotherapy
Common side effects
- Hypertension
- Thromboembolism
- Headache
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: